- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | siRNA Transfection Reagent, Lipid Nanoparticle-Based |
| Catalog No. | ATR-CTR-0007 |
| Description | A specially designed cationic lipid nanoparticle formulation optimized for the efficient and reproducible delivery of small interfering RNA duplexes into mammalian cells for gene silencing studies. |
| Intended Use | Delivery of synthetic siRNA and dicer-substrate siRNA into mammalian cells for RNA interference experiments, gene knockdown validation, and functional genomics screening in multi-well plate formats. |
| Principle / Technology | Smaller and more rigid lipid nanoparticles compared to DNA transfection reagents are optimized for compaction of 21–27 bp siRNA duplexes; modified lipid composition enables efficient endosomal release with minimal innate immune activation through TLR pathways. |
| Detection Method | Target gene mRNA knockdown by RT-qPCR, protein knockdown by Western blot or flow cytometry, off-target gene expression profiling |
| Sample Type | Adherent and suspension mammalian cell lines, primary cells compatible with lipid delivery |
| Performance Range / Specifications | mRNA knockdown >80% for targets with <100 copies per cell at 10–50 nM siRNA; >95% knockdown possible for highly expressed targets at 50–100 nM |
| Sensitivity / LOD | N/A |
| Specificity | N/A |
| Reaction Conditions / Protocol | Dilute siRNA to desired concentration in serum-free medium; dilute reagent separately (0.2–0.5 µL per pmol siRNA); mix and incubate 10–20 min; add to cells in complete medium; harvest 24–72 hours for knockdown assessment. |
| Components / Formulation | Proprietary cationic lipid blend, co-lipid, ethanol-water vehicle, 0.2 µm filtered |
| Storage Conditions | 2–8°C; do not freeze |
| Shelf Life | 12 months |
| Package Specifications | 0.75 mL (for 250 transfections in 24-well), 1.5 mL, 5 mL |
| Product Form | Liquid, sterile-filtered |
| Quality Control | GAPDH knockdown validation in HeLa cells (≥80% at 10 nM), IFN-beta and OAS1 induction measurement for innate immune activation, cytotoxicity |
| Key Features | High knockdown efficiency; low innate immune activation; low siRNA concentration required; serum compatible; validated for genome-wide siRNA screening |
For research use only, not for clinical use.
|
There is no product in your cart. |
Copyright © 2026 Alta DiagnoTech. All rights reserved.
